Persephoni Bio: Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury
Essential brief
Persephoni has partnered with SelSym Biotech to develop the first shelf-stable, blood-type agnostic hemostatic therapy intended for use at the point of injury. This collaboration aims to address th
Key topics
Key facts
Highlights
Why it matters
The development of a blood-type agnostic, shelf-stable hemostatic therapy represents a significant advancement in emergency trauma care. It addresses the urgent need for rapid bleeding control at injury sites without the delays associated with blood typing. This innovation could improve survival rates and treatment efficiency in both civilian and military settings.
Persephoni has announced a partnership with SelSym Biotech to advance the development of a novel hemostatic therapy that is both shelf-stable and blood-type agnostic. This therapy is designed specifically for use at the point of injury, where rapid bleeding control is critical but current options are limited. The collaboration focuses on creating a product that can be easily stored and deployed in emergency settings without the need for blood typing, which can delay treatment.
SelSym Biotech brings expertise in biotechnology to the partnership, aiming to develop a therapy that can effectively control bleeding regardless of the patient's blood type. This approach addresses a significant gap in trauma care, as existing treatments often require blood matching or have limited shelf lives.
The new hemostatic therapy is expected to improve outcomes in emergency medicine by enabling faster intervention at injury sites, potentially reducing mortality and complications associated with uncontrolled bleeding. The shelf-stable nature of the product also facilitates storage and transport, making it suitable for use in various environments, including military and remote settings.
This collaboration reflects a growing focus on innovative solutions in trauma care, emphasizing the importance of rapid, accessible treatments that can be administered immediately after injury. By eliminating the need for blood typing, the therapy could streamline emergency response protocols and enhance patient survival rates.
Persephoni and SelSym Biotech plan to continue research and development efforts to bring this therapy to market, aiming to fill a critical unmet need in bleeding control at the point of injury.
Key topics in this update include persephoni, persephoni backs selsym biotech, and persephoni backs selsym.